BlueCross BlueShield of Tennessee Medical Policy Manual

Natural Orifice Transluminal Endoscopic Surgery

DESCRIPTION

Natural Orifice Transluminal Endoscopic Surgery (NOTES) has been proposed as a less invasive surgical approach that combines endoscopic and laparoscopic techniques to access an internal body cavity through a natural orifice (mouth, anus, vagina, or urethra).

POLICY

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.

ADDITIONAL INFORMATION

Scant clinical evidence is available at this time to demonstrate the safety or efficacy of natural orifice transluminal endoscopic surgery (NOTES). The majority of the existing NOTES research reports on animal testing. The first NOTES procedures to be evaluated in humans have been relatively common, uncomplicated procedures such as cholecystectomy. Available evidence is insufficient to determine whether natural orifice transluminal endoscopic surgery is at least as beneficial as any established surgical intervention.

The American Society of Gastrointestinal Endoscopy does not have a practice guideline regarding this new technology. They do state that there is insufficient data to make recommendations on antibiotics before NOTES, however the use of prophylaxis seems reasonable.

SOURCES

American Society of Gastrointestinal Endoscopy. (2008, May). Antibiotic prophylaxis for GI endoscopy. Retrieved October 10.2010 from http://www.guideline.gov/content.aspx?id=12809.

Rattner, D. & Kalloo, A.; ASGE/SAGES Working Group. (2006). ASGE/SAGES working group on natural orifice transluminal endoscopic surgery white paper. Surgical Endoscopy, 22 (1), 329-333. (Level 5 Evidence)

U.S. Food and Drug Administration. (2007, March). Center for Devices and Radiological Health. 510(k) Premarket Notification Database. K062875. Retrieved October 26, 2010 from http://www.accessdata.fda.gov/cdrh_docs/pdf6/K062875.pdf.

U.S. Food and Drug Administration. (2010, June). Center for Devices and Radiological Health. 510(k) Premarket Notification Database. K082102. Retrieved October 7, 2010 from http://www.accessdata.fda.gov/cdrh_docs/pdf8/K082102.pdf.

U.S. Food and Drug Administration. (2009, November). Center for Devices and Radiological Health. 510(k) Premarket Notification Database. K092400. Retrieved March 17, 2011 from http://www.accessdata.fda.gov/cdrh_docs/pdf9/K092400.pdf.

White, W., Haber, G., Doerr, M. & Getman, M., (2009) Natural orifice transluminal endoscopic surgery. Urologic Clinics of North America, 36 (2), 147-155. (Level 5 Evidence)

ORIGINAL EFFECTIVE DATE:  5/9/2009   

MOST RECENT REVIEW DATE:  11/11/2010

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.

additional keyword(s): Transoral NOTES